Three Leading Pharmaceutical Trade Publications Highlight InNexus Biotechnology Inc.’ Proprietary Technology, Dynamic Cross Linking
BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), was recently featured in three leading pharmaceutical publications, Drug Delivery Technology, Innovations in Pharmaceutical Technology, and PFQ Magazine. This media exposure is part of an aggressive public relations initiative to elevate awareness of the Company’s proprietary technology, world-class team and pharmaceutical industry partners.